Compare BCDA & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCDA | SLE |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 177.4M |
| IPO Year | 2009 | 2019 |
| Metric | BCDA | SLE |
|---|---|---|
| Price | $1.12 | $4.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $25.00 | ★ $60.00 |
| AVG Volume (30 Days) | 162.2K | ★ 2.1M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $479,000.00 | ★ $2,064,000.00 |
| Revenue This Year | N/A | $24.86 |
| Revenue Next Year | N/A | $49.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 90.41 |
| 52 Week Low | $0.75 | $0.48 |
| 52 Week High | $2.27 | $11.43 |
| Indicator | BCDA | SLE |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 59.76 |
| Support Level | $0.78 | $3.27 |
| Resistance Level | $1.26 | $5.24 |
| Average True Range (ATR) | 0.06 | 0.43 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 50.73 | 68.29 |
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.